Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVP-001 (manganese-based MRI contrast agent) in CNS lesions
NCT06322342Phase 2Completed
- Sponsor
- Reveal Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of manganese-based contrast agent RVP-001, sponsored by Reveal Pharmaceuticals. Started Aug 2024; status: completed.
02
Drugs
manganese-based contrast agent RVP-001
Beyond the preview
Go deeper on NCT06322342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06322342.